A RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER TRIAL TO ASSESS THE SAFETY AND EFFICACY OF NB-001 IN CHILDREN AND ADOLESCENTS WITH 22Q11 DELETION SYNDROME

Registry ID

NB-001-01

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

NOBIAS THERAPEUTICS, INC

Start date

2022-05-19

Completion date

2024-12-16

Last update

2021-03-11

Conditions

• 22Q11 DELETION SYNDROME

Related clinical trials

• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED NNZ-2591 COMPARED WITH PLACEBO IN PEDIATRIC PARTICIPANTS WITH PHELAN MCDERMID SYNDROME
• A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS

View on source registry